Abstract: The present invention relates in a first aspect to a mutated adeno-associated virus (AAV) capsid protein or fragment thereof having an insert composed of an oligopeptide optionally having further amino acids representing linker sequences flanking both sites of said oligopeptide. These mutated AAV capsid proteins are more efficient in targeting hepatic tissue, hepatocytes, hepatic cells and cell lines or hepatocellular carcinoma (HCC) with partially higher specificity. Further, a mutated AAV particle comprising the mutated AAV capsid protein according to the present invention is provided. In addition, a nucleic acid encoding the mutated AAV capsid protein according to the present invention is identified together with a corresponding nucleic acid vector, in particular, a plasmid. In addition, a host cell containing the nucleic acid vector or the nucleic acid molecule according to the present invention.

Abstract: The present invention relates to methods for predicting the efficacy, safety and toxicity of substances, e.g. of drugs and prodrugs. Furthermore, the present invention relates to a method for the stratification of mammalians for the treatment of a disease. Moreover, the present invention provides for kits and its use for determining the efficacy, safety and toxicity of substances, in particular of drugs and prodrugs. The present invention allows for the selection of therapeutic regimens utilizing host genetic information, including gene sequence variances. The methods for identification of the specific DNA sequence variations according to the present invention include both in vitro and in vivo approaches.